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A programme to review the drug treatment of 2 15 adults with epilepsy and learning disabilities occurred in LeiceStershire between 
1982 and 1985. In 1997, a Leicestershire-wide study of epilepsy suffered by adults with learning disabilities was undertaken. 
The study sought information about many aspects of the epilepsy including the prescribing of medicines. One hundred and 
thirty-eight adults were common to both studies. A greater proportion was suffering active epilepsy in 1997 than in 1985. The 
deterioration in seizure control occurred despite an increase in polypharmacy, the introduction of new antiepileptic drugs and in 
some cases increases in dosage. 
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INTRODUCTION 
Follow-up studies of epilepsy in learning disabili- 
ties are few in number. Of the available studies most 
are of the prognosis for children with epilepsy and 
learning disabilities’q2, reports of the effects of drug 
alteration3-” or follow-up studies of mortality”-‘3. 
Studies of prognosis for children with epilepsy and 
learning disabilities have generally reflected a positive 
outcome. Goulden et al. ’ reported that by the age of 
22 years 39% had achieved 5 years free of seizures 
and that this performance varied according to the na- 
ture and cause of the learning disabilities. Brorson and 
Wranne* studied children aged O-19 years who had 
active epilepsy in a defined Swedish population. Their 
12-year follow-up showed long-standing remission oc- 
curring in 124 of the 194 children with abnormal neu- 
rology and/or learning disabilities. Similar cohort stud- 
ies of adults with learning disabilities are not available, 
although studies of the non-learning disabled popu- 
lation with epilepsy would suggest that many should 
achieve remission from seizurest4. 
There have been numerous studies that report the 
effects of drug alterations involving people with leam- 
ing disabilities and epilepsy. These studies have gen- 
erally aimed to reduce polypharmacy of antiepileptic 
drugs, withdraw antiepileptic drugs or change to newer 
medicines. The results achieved by Pellock and Hunt3 
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are typical. They showed a 19% reduction of polyphar- 
macy, a 12.7% rate of discontinuation and reduction of 
the use of barbiturates. Interestingly, half of those who 
discontinued antiepileptic drug treatment required its 
reinstatement. 
The follow-up studies of mortality have generally 
demonstrated that epilepsy is associated with signifi- 
cantly increased mortality in persons with learning dis- 
abilities. Fosgren et al. 1 ’ also showed that increased 
mortality is related to seizure type and frequency but 
that the cause of death was seldom directly related to 
the seizures. 
Most studies of epilepsy in learning disabilities in- 
dicate that the first seizures usually occur in the first 
5 years of life’ ‘* 15. Brodtkorb16 in a study of 63 insti- 
tutionalized adults with epilepsy and learning disabili- 
ties found 29% to have suffered a first seizure after the 
age of 20. Branford et al.17, on the other hand, found 
in only 7% of the study population that seizures started 
after the age of 20. Fosgren et al. I’ showed that the 
prevalence of epilepsy in learning disabilities remains 
constant for much of the period from 20-60 years. 
Collacott et ~1.~ reported on a 4-year drug review 
programme of 215 adults with epilepsy and learning 
disabilities who lived in Leicestershire, UK. The re- 
view programme which occurred between 1982 and 
1985 comprised all people living in institutional care. 
The programme achieved a reduction of polypharmacy 
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of antiepileptic drugs, a change from the prescribing 
of phenobarbitone, primidone and phenytoin to carba- 
mazepine and sodium valproate, and for some people a 
reduction in the frequency of seizures. For many of the 
215 persons who are still alive both the medical service 
and the style of care will have changed significantly. 
With the closure of the institutions many now live in 
community settings and the treatment of their epilepsy 
is supervised by a general practitioner and/or special- 
ists. In addition, since 1985 four new antiepileptic drugs 
(vigabatrin, lamotrigine, gabapentin and topiramate) 
have reached the market and are indicated for people 
with refractory seizures. 
One might expect that for the remainder of the 1982- 
1985 review programme cohort that: (1) more would be 
in remission; (2) the prescribing of phenytoin, pheno- 
barbitone and primidone would be further reduced; and 
(3) the introduction of new drugs would have reduced 
the frequency of seizures for some. It was therefore 
decided to study further this cohort of individuals with 
learning disabilities and epilepsy 12 years after the end 
of the drug review programme. 
In 1997, a study of all people with learning disabili- 
ties and epilepsy who live in Leicestershire was under- 
taken. This study included those persons who partici- 
pated in the review programme of 1982-l 985 and who 
were still alive and living in Leicestershire. This paper 
presents a comparison of the epilepsy and its treatment 
for those people common to both the 1982-1985 pro- 
gramme and the 1997 study. 
MATERIALS AND METHOD 
Collacott et QZ.~, reported on a 4-year review of 215 
people with epilepsy and learning disabilities who lived 
in institutional care. By the end of the review (1985) 
172 people were left in the programme and informa- 
tion about the frequency of their seizures and use of 
antiepileptic drugs throughout both the review pro- 
gramme and the 5 years prior to the programme was 
noted. 
In 1997, a study of epilepsy in adults with learn- 
ing disabilities who lived in Leicestershire was under- 
taken. The study involved the completion of an ex- 
tensive questionnaire by the key carers of 532 adults 
known to suffer both epilepsy and learning disabili- 
ties. Information gathered about each person included: 
demographic details; the nature of the epilepsy; the 
treatment of the epilepsy, including current access to 
services; details of the drug therapy; and the effect of 
epilepsy on the quality of life. 
One hundred and thirty-eight adults were common 
to both studies and comparisons were made of their 
frequency of seizures and prescription of medicines. 
In addition, two other comparisons were made. The 
first was of the 138 survivors and the 34 for whom there 
was no follow-up information, and the second was of 
the 138 of the original cohort and 172 other adults with 
learning disabilities and epilepsy aged over 35 years. 
RESULTS 
One hundred and thirty-eight adults with learning dis- 
abilities and epilepsy were common to both the re- 
view programme of 1982-1985 and the survey of 
1997. Eighty (58%) were male and 58 (42%) female. 
Their mean age was 47 years (f12.59) and they were 
predominantly profoundly learning disabled (63%). 
Seventy-four (54%) continued to live in NHS accom- 
modation, whilst the remaining 64 (46%) lived in com- 
munity accommodation provided by a multitude of 
statutory, voluntary and private organizations. 
Of the 138 adults, 127 (92%) were confirmed to be 
suffering from epilepsy. In nine cases the carers main- 
tained that the person did not differ from epilepsy, 
whilst in two cases they were unsure. Tonic-clonic 
seizures were the most commonly reported (53%), fol- 
lowed by absences (3 1%) and myoclonic jerks (15%). 
In 47% more than one seizure type occurred. 
At the end of the drug review programme (1982- 
1985) 33 people had not suffered a seizure for at lest 
5 years (inactive epilepsy), 25 were in remission (no 
seizure for 3-5 years) and the remaining 80 were still 
suffering seizures (active epilepsy). The figures for the 
survey of 1997 were 27, 13 and 98, respectively (see 
Table 1). 
Table 1: A comparison of seizure frequency 1985 vs. 1997. 
No. of adults No. of adults 
Status of epilepsy in 1985 (%) in 1997 (%) 
Inactive epilepsy 
(no seizures for 5 years) 33 (24%) 27 (20%) 
Epilepsy in remission 
(no seizures for 3-5 years) 25 (18%) 13 (9%) 
Active epilepsy 80 (58%) 98 (71%) 
Total 138 (100%) 138 CIOO%j 
x2 = 6 21. df. = 2; p < 0.05. . 3 
Table 2: The polypharmacy of antiepileptic drugs in 1985 and 
1997. 
Number of No. of adults No. of adults 
antiepileptic drugs in 1985 in 1997 
0 0 15 
1 103 67 
2 24 38 
3 5 16 
4 1 2 
Information missing 5 - 
Total 138 138 
x2 = 36.88. 1. df = 5. 9 p < 0.001. 
The drug review programme of 1982-1985 had 
focused particular attention on the eradication of 
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Table 3: The use of antiepileptic drugs in 1985 and 1997. 
Antiepileptic 
1985 I997 
No. of adults Median No. of adults Median 
dwz 
Carbamazepine 
receiving drug daily dose (mg) receiving drug daily dose (mg) 
85 900 106 900 
Sodium valproate 34 1200 46 2000 
Phenytoin 5 250 4 250 
Phenobarbitone 28 180 IO I35 
Primidone 1 100 1 I50 
Ethosuximide - - 3 750 
Clonazepam 1 6 4 1.75 
Clobazam 5 20 I 20 
Lamohigine - - 8 I50 
Gabapentin - - 9 1200 
Topiramate - - I 800 
Vigabatrin - - 6 2000 
polypharmacy of antiepileptic drugs. Table 2 shows 
the number of antiepileptic drugs received in 1985 
and 1997. 
The eradication of the older antiepileptic drugs (phe- 
nobarbitone, primidone and phenytoin) is an aim of 
most antiepileptic drug review programmes. Table 3 
provides information about the use of antiepileptic 
drugs in 1985 and 1997. 
Information was gathered about those people in- 
cluded in the review programme of 1982-1985 but for 
whom no 1997 data were available, to see if the surviv- 
ing 138 persons represented a particularly refractory 
sample. Ninety percent had died and, if still alive in 
1997, would have presented with a greater mean age 
(mean of 56 years vs. 47 years) than the survivors. 
More suffered active epilepsy at the end of the review 
programme of 1982-1985 (73% vs. 58%) and more re- 
ceived two or more antiepileptic drugs (38% vs. 22%) 
than the 138 people common to both time periods. In 
most other aspects the two groups were similar. These 
findings would suggest that those who had died since 
1985 represented a more refractory group than the 
survivors. 
Comparison was also made with 172 other persons 
with epilepsy and learning disabilities aged over 35 and 
living in Leicestershire. This comparison was made to 
see if the institutional background of the review group 
had in some way biased the sample. Although there 
were minor differences in the proportion of patients 
suffering particular seizure types there were no sig- 
nificant differences between the groups in the propor- 
tion achieving remission. The number prescribed two 
or more antiepileptic drugs was slightly higher (5 1% vs. 
46%) for the 172 than the 138 of the review programme. 
These findings would suggest that the cohort com- 
mon to both time periods was not significantly different 
from the remainder of those with epilepsy and learning 
disabilities. 
DISCUSSION 
The findings of this follow-up study were contrary to 
expectation. The introduction of new therapies for the 
treatment of epilepsy, the expectation of continued re- 
mission from seizures and of further remission with 
age should have resulted in a reduction of the numbers 
with active epilepsy with time. In fact, the opposite 
has occurred. There are a number of possible explana- 
tions for the findings. The first could be that with in- 
creased age some adults with learning disabilities and 
epilepsy suffer a worsening of their seizure frequency. 
This may parallel that seen in the general population 
where an increased incidence of epilepsy is associated 
with cerebrovascular disease and degenerative neuro- 
logical conditions such as Alzheimer’s disease14. A 
second explanation could be seen as support for the 
need for a specialist epilepsy review clinic. During the 
period from 1982-1985 both epilepsy and the use of 
antiepileptic drugs were the focus of an expert team. 
This team achieved significant improvements in seizure 
frequency for many patients and at the same time a 
reduction in the polypharmacy of antiepileptic drugs. 
Since 1985, epilepsy has been one of a number of issues 
reviewed either by the general practitioners or the con- 
sultant psychiatrists specializing in learning disabili- 
ties. Branford and Co11acott’8 had noted differences in 
the use of antiepileptic drug treatment by patients re- 
ceiving GP care rather than specialist care, but it was 
difficult to know if that was a factor in this study. A 
third explanation could be that the change to the provi- 
sion of care from medical-style ward settings to small 
‘homely’ settings in some way increased the factors 
which lead to a worsening of seizures. 
An alternative explanation was that the cohort as a 
particularly refractory or unusual group. This could 
be somewhat discounted by the finding that many of 
those who had died since 1985 were those who suffered 
more refractory epilepsy and received more antiepilep- 
tic drugs. In addition, the performance in achieving re- 
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mission was almost identical in another sample of per- 
sons with epilepsy and learning disabilities who were 
aged over 35 years and living in Leicestershire. 
Studies of mortality amongst those with learning dis- 
abilities and epilepsy “-13 show that for those with ac- 
tive epilepsy and frequent seizures the likelihood of 
premature death is high. This would increase the likeli- 
hood that those who survive are in remission and should 
have a greater expectation of an improvement in per- 
formance. 
The introduction of new drug treatments for epilepsy 
does not appear to have resulted in any improvement 
in the overall performance. Bhaumik et al. I9 reported 
on a naturalistic study of the efficacy of the first three 
new antiepileptic drugs (vigabatrin, lamotrigine and 
gabapentin) on 50 adults with learning disabilities. 
They found the new drugs to be of limited efficacy and 
to cause many side effects. The introduction of the add- 
on therapies rarely resulted in a subsequent reduction 
in the number of older antiepileptic drugs, the resulting 
effect being an increase in the number of antiepileptic 
drugs prescribed. 
The other major changes that occurred to the pre- 
scribing of medicines were the continued reduction of 
the prescribing of phenobarbitone and increased pre- 
scribing of sodium valproate and carbamazepine. This 
change would be in line with the aims of the original re- 
view programme and constitute good medical practice. 
In the 1982-1985 programme an increased mean 
dose for sodium valproate was noted (117 1 mg and 
1516 mg). By 1997, the median dose had escalated to 
2000 mg, whereas a similar increase had not occurred 
with carbamazepine. The reason for this could be that 
sodium valproate is possibly prescribed for seizures 
which are more refractory to treatment. 
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